Bluechiip Ltd (ASX: BCT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Bluechiip Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Bluechiip Ltd (ASX: BCT)
Latest News
Technology Shares
Bluechiip (ASX:BCT) share price explodes 63% on Fujifilm deal
BCT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Bluechiip Ltd
Bluechiip Ltd is engaged in the development and commercialization of a wireless tracking solution. It serves healthcare and life science, security, defence, and manufacturing industries. Its product includes Retrofit Button For CryoVials; CryoVial Box; CryoTag; Matchbox Reader; Multi-Vial Reader; Hand-Held Reader; Stream Sample-Management Software; Blood Cassettes; and Towers/Racks/Frames.
BCT Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
27 Sep 2024 | $0.00 | $0.00 | 0.00% | 257,397 | $0.00 | $0.00 | $0.00 |
26 Sep 2024 | $0.00 | $0.00 | 0.00% | 43,261 | $0.00 | $0.00 | $0.00 |
25 Sep 2024 | $0.00 | $0.00 | 0.00% | 3,750,700 | $0.00 | $0.00 | $0.00 |
20 Sep 2024 | $0.00 | $0.00 | 0.00% | 5,100 | $0.00 | $0.00 | $0.00 |
19 Sep 2024 | $0.00 | $0.00 | 0.00% | 464,913 | $0.00 | $0.00 | $0.00 |
12 Sep 2024 | $0.00 | $0.00 | 0.00% | 23,750 | $0.00 | $0.00 | $0.00 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
26 Sep 2024 | Iain Kirkwood | Issued | 7,954,545 | $35,000 |
Director remuneration. Nil cash consideration
|
26 Sep 2024 | Michael Ohanessian | Issued | 4,545,454 | $20,000 |
Director remuneration. Nil cash consideration
|
26 Sep 2024 | Andrew McLellan | Issued | 4,268,323 | $18,780 |
Director remuneration. Nil cash consideration
|
26 Sep 2024 | Andrew Cox | Issued | 4,545,454 | $20,000 |
Director remuneration. Nil cash consideration
|
16 Sep 2024 | Michael Ohanessian | Issued | 2,272,727 | $9,999 |
Placement.
|
09 Apr 2024 | Andrew McLellan | Issued | 3,000,000 | $21,000 |
Issue of securities. 7,766,667 Performance Rights
|
14 Mar 2024 | Andrew Cox | Issued | 3,571,428 | $24,999 |
Rights issue.
|
14 Mar 2024 | Andrew McLellan | Issued | 1,428,571 | $9,999 |
Rights issue.
|
14 Mar 2024 | Michael Ohanessian | Issued | 4,409,912 | $30,869 |
Rights issue.
|
14 Mar 2024 | Michael Ohanessian | Issued | 3,617,382 | $25,321 |
Rights issue.
|
14 Mar 2024 | Iain Kirkwood | Issued | 8,623,415 | $60,363 |
Rights issue.
|
14 Mar 2024 | Iain Kirkwood | Issued | 15,825,644 | $110,779 |
Rights issue.
|
14 Dec 2023 | Michael Ohanessian | Issued | 1,190,477 | $25,000 |
Placement. As per announcement on 14-12-2023
|
14 Dec 2023 | Iain Kirkwood | Issued | 6,380,953 | $150,000 |
Placement.
|
14 Dec 2023 | Andrew McLellan | Issued | 714,286 | $15,000 |
Placement. As per announcement on 14-12-2023
|
01 Nov 2023 | Andrew McLellan | Expiry | 3,133,333 | $62,666 |
As advised by the company. 4,766,667 Performance Rights, lapsed
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Iain MacGregor Crawford Kirkwood | Non-Executive DirectorNon-Executive Chairman | Nov 2007 |
Mr Kirkwood is a private consultant, investor and non-executive Director. He has practical and operational experience gained from a financial career spanning 35 years in a range of industries including auditing, resources, manufacturing and latterly healthcare in Australia, Britain and the USA. He started his career at Arthur Andersen & Co in London. During his career, he has held a range of senior financial and general management positions, including Woodside Petroleum Limited, Santos Limited, Pilkington plc, F.H. Faulding & Co Limited and Clinuvel Pharmaceuticals Limited.
|
Mr Michael B. Ohanessian | Non-Executive Director | Dec 2014 |
Mr Ohanessian has executive experience gained from technology-related businesses with a mixture of operational, strategic and leadership capabilities. Following a ten-year career at Mobil Oil, Michael joined the Boston Consulting Group where he consulted to clients in a range of industries which include banking, airlines, mining, packaging, sports, oil and gas, retailing and biotechnology. Michael later moved on to be the CEO of Vision BioSystems, a division of the former publicly listed Vision Systems Limited, where he transformed the business over seven years from a small unprofitable contract manufacturer into a vertically integrated, profitable and growing medical diagnostics business with distribution to over 60 countries. He has also served as Chief Executive of Genetic Technologies Limited and has been involved in investment management and corporate advice with Lion Capital.
|
Mr Andrew McLellan | Chief Executive OfficerManaging Director | Jan 2015 |
Mr McLellan has experience in innovation and commercialisation combined with technical and operational experience. Prior to joining Bluechiip, he was the CEO of Advanced Manufacturing Co-operative Research Centre (AMCRC) which he now serves as a non- executive Director. Andrew focused on bringing together industry and research to develop and commercialise ground-breaking innovations. He has held a range of senior positions including Director at Leica Microsystems Pty Ltd, Vice President of Marketing and Business Development North America and Director of Product Management at Vision BioSystems Pty Ltd.
|
Mr Andrew Cox | Non-Executive Director | Jul 2017 |
Mr Cox has experience in emerging and international markets. Andrew was a co-founder and former chairman of private equity-funded media/ technology business Inlink (sold to ASX-listed oOh! Media Ltd in 2015, and is a co-founder of iPro Pty Ltd. Andrew began his career with KPMG in Melbourne before moving to China and Hong Kong, where he spent seven years with SG Warburg, the Australian Trade Commission and Ernst & Young. He is a member of the Translation and Commercialisation Committee of the Murdoch Children's Research Institute and is fluent in Mandarin Chinese.
|
Ms Patricia Vanni | Company Secretary | Jul 2024 |
-
|
Patricia Vanni | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Hsbc Custody Nominees (Australia) Limited | 100,834,755 | 14.13% |
Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> | 31,943,930 | 4.48% |
J P Morgan Nominees Australia Pty Limited | 29,027,271 | 4.07% |
Mutual Trust Pty Ltd | 18,381,336 | 2.58% |
Dr Stephen Frederick Woodford | 18,200,000 | 2.55% |
Mr Iain Macgregor Crawford Kirkwood | 15,774,949 | 2.21% |
Allhc Pty Ltd <Sam Hupert Family A/C> | 13,040,000 | 1.83% |
Bramscorp Pty Ltd <Gilbert Family S/Fund A/C> | 8,783,102 | 1.23% |
Edward St Consulting Pty Ltd <Kirkwood Family S/Fund A/C> | 8,320,037 | 1.17% |
Talento Holdings Pty Ltd | 7,866,667 | 1.10% |
Citicorp Nominees Pty Limited | 7,179,441 | 1.01% |
Richard Seville And Associates Pty Ltd <The Seville Super Fund A/C> | 6,961,567 | 0.98% |
Hsbc Custody Nominees (Australia) Limited - A/C 2Mr Michael Bernard Ohanessian | 6,959,737 | 0.98% |
Spurgin Smsf Pty Ltd <Spurgin Smsf A/C> | 6,750,000 | 0.95% |
Alltogether Pty Ltd <Alltogether Super Fund A/C> | 6,001,322 | 0.84% |
Brendan Luxton Investments Pty Ltd | 6,000,000 | 0.84% |
Corpdan Investments Pty Limited <Mcguirk Super Fund A/C> | 5,709,468 | 0.80% |
Ansata Investments Pty Ltd <Ansata Investment A/C> | 5,674,087 | 0.80% |
Belladonna Holdings Pty Ltd <Belladonna Super Fund A/C> | 5,460,601 | 0.77% |
Adam James Winstanley & Mrs Jody Annette Winstanley <Winsland Superannuation A/C> | 5,065,032 | 0.70% |